The Centers for Medicare & Medicaid Services Aug. 15 released a state funding notice for the Cell and Gene Therapy Access Model. The CGT Access Model will test whether a CMS-led approach to developing and administering outcomes-based agreements for cell and gene therapies improves Medicaid beneficiaries’ health outcomes, broadens access to innovative treatment and reduces health care expenditures. It will initially focus on gene therapies for sickle cell disease. The notice includes an opportunity for applicants to apply for cooperative agreement funding to support participation in the CGT Access Model. Applicants must apply for participation in the model through a state applications request and apply for funding through the state funding notice, both of which are due Feb. 28, 2025. The award date is anticipated for July 1, 2025. 

Headline
The AHA April 23 released a blog responding to a report issued April 22 by Paragon Health Institute. The blog highlights how the report relies on a long list…
Blog
Public
In think‑tank reports, like the one released this week by Paragon Health Institute, hospitals are often reduced to abstractions — payment rates, charts,…
Headline
The Centers for Medicare and Medicaid Services April 8 issued guidance on implementing a provision within the reconciliation bill passed in July 2025 regarding…
Headline
The Centers for Medicare & Medicaid Services April 2 announced the release of new data on health care utilization and prices at the provider and service…
Headline
The Centers for Medicare & Medicaid Services Innovation Center March 24 announced the launch of a new model under Medicaid and the Children’s Health…
Headline
The Centers for Medicare & Medicaid Services March 11 issued guidance to state survey agency directors clarifying and reinforcing the roles and…